Pharmaceutical News

RSS

Aspirin may benefit HIV-infected women at risk of cervical cancer

Research conducted by NewYork-Presbyterian Hospital/Weill Cornell Medical Center global health investigators and cancer specialists in New York, Qatar and Haiti suggests that aspirin should be evaluated for its ability to prevent development of cervical cancer in HIV-infected women.

19 Jan 2012

FDA, pharmaceutical industry reach agreement on user-fee plan for generics

The Food and Drug Administration would collect hundreds of millions of dollars in new fees from pharmaceutical companies to help speed up the review of generic drugs, under an agreement with the industry released by the agency on Friday.

19 Jan 2012

New York Times examines history of malaria drug artemisinin

The New York Times examines the history of the Chinese drug artemisinin, "hailed as one of the greatest advances in fighting malaria ... since the discovery of quinine centuries ago," noting the drug "is being talked about as a candidate for a Nobel Prize in Medicine."

19 Jan 2012

Drug benefit managers unveil ads to explain what they do

The trade group for pharmaceutical benefit managers announced an advertising campaign about PBMs, while Congress and federal regulators weigh a $29 billion merger between Express Scripts and Medco.

19 Jan 2012

Patients with PsA may benefit from new medications and surgeries

Medications or biologic agents that target T-cells, white blood cells involved in the body's immune system, appear to offer significant benefit to patients suffering from psoriatic arthritis (PsA), a type of arthritis that affects up to 48 percent of patients with the skin disease psoriasis, according to a new review article in the Journal of the American Academy of Orthopaedic Surgeons.

19 Jan 2012

Exposure to metformin may decrease risk of cancer

In 2005, news first broke that researchers in Scotland found unexpectedly low rates of cancer among diabetics taking metformin, a drug commonly prescribed to patients with Type II diabetes. Many follow-up studies reported similar findings, some suggesting as much as a 50-per-cent reduction in risk.

19 Jan 2012

C&EN explains logic behind odd-sounding generic names

Oseltamivir. Esomeprazole. Trastuzumab. Where do drugs get those odd-sounding generic names? The answers are in the current issue of Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, the world's largest scientific society, which explains the logic behind the tongue-twisters.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Dogs with spinal cord injuries may soon benefit from experimental drug

Dogs with spinal cord injuries may soon benefit from an experimental drug being tested by researchers at the University of California, San Francisco (UCSF) and Texas A&M College of Veterinary Medicine & Biomedical Sciences — work that they hope will one day help people with similar injuries.

19 Jan 2012

Watson introduces new oral contraceptive, Vestura

Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Pharma, Inc. has launched Vestura(TM), a generic version of Bayer HealthCare Pharmaceuticals Inc.'s Yaz(R) oral contraceptive product.

18 Jan 2012

EMA grants Orphan Drug Designation to Ceptaris' chlormethine gel for treatment of CTCL

Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Ceptaris' investigational drug, chlormethine gel, for the treatment of Cutaneous T-Cell Lymphoma.

18 Jan 2012

Pfizer and Medivation drop further testing of failed Alzheimer’s drug

A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.

18 Jan 2012

Counterfeit malaria drugs endanger millions of lives

According to researchers fake and poor quality anti-malarial drugs are threatening efforts to control the disease in Africa and could put millions of lives at risk. These counterfeit medicines could harm patients and promote drug resistance among malaria parasites, warns the study, funded by the Wellcome Trust.

18 Jan 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.

18 Jan 2012

Mandatory pre-contract performance-enhancing drugs screening policy for potential UFC athletes

Continuing a commitment to the health and safety of its athletes, the Ultimate Fighting Championship announced today that all potential UFC and STRIKEFORCE signees will be subject to a mandatory pre-contract screening for performance-enhancing drugs. Beginning Jan. 1, 2012, all incoming athletes will be tested prior to finalizing a contract with the world's premier mixed martial arts organization.

18 Jan 2012

Paragon receives JVAP-CBMS contract from DoD

Paragon Bioservices, Inc., a Baltimore-based CMO focused on the process development and manufacturing of biologics, announced today that it has been awarded a JVAP-CBMS contract from the Department of Defense (DoD) for the vaccine development and subsequent GMP manufacturing of the "VEE Replicon Particle Trivalent Filovirus Vaccine."

18 Jan 2012

Bioengineers receive $2 million NIH grant to develop new toxicology tests

Chemicals in pharmaceutical drugs can obviously save lives. But as more and stronger chemicals have been introduced, our basic knowledge of the broader health impact of all these chemicals has not kept up with the rapid pace of innovation. There is exceptionally little information on how chemicals in our drugs and also in the environment around us, including on the food we eat, impact some of the most important cells in our body: stem cells. Without basic knowledge and tests on the impact of chemicals on our stem cells, we may be unwittingly damaging essential regenerative functions in our body.

18 Jan 2012

Alpha-1-antitrypsin may reduce effects of GVHD

A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants.

18 Jan 2012

EMA approves Genzyme's Fabrazyme manufacturing plant in Framingham

Genzyme, a Sanofi company, announced today that the European Medicines Agency (EMA) has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme.

18 Jan 2012